[Form 4/A] Inhibikase Therapeutics, Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Inhibikase Therapeutics, Inc. (IKT) has filed an amended Form 4 (Form 4/A) for Chief Executive Officer and Director Mark T. Iwicki. The sole purpose of the amendment is to correct two data points that were misstated in the original Form 4 filed on 25 Feb 2025: (i) the exercise price of a stock-option award and (ii) its expiration date.

Key terms of the option grant (originally awarded 21 Feb 2025):

• Derivative security: Non-qualified stock option to purchase 602,346 shares of common stock.
• Corrected exercise price: $2.97 per share.
• Corrected expiration date: 21 Feb 2035 (10-year term).
• Vesting schedule: 48 substantially equal monthly installments beginning 21 Mar 2025, contingent on continued employment.
• Ownership status: Shares are held directly by the reporting person.

The filing does not report new purchases or sales of shares; it is an administrative correction. Nevertheless, the option grant, if fully exercised, would result in issuance of up to 602,346 new shares, creating a modest potential dilution for existing shareholders. Because the option vests over four years, dilution would be gradual and contingent on share-price appreciation above $2.97.

Investor takeaways: (1) Management has rectified an earlier clerical error, demonstrating regulatory compliance; (2) the CEO’s long-term incentive package now has confirmed terms, aligning his interests with shareholders; (3) no immediate cash outflow or revenue impact is associated with the amendment.

Positive

• Improved transparency: Company swiftly corrected prior misreported option terms, reinforcing regulatory compliance.
• Long-term incentive alignment: 602,346 options vest over 48 months, tying CEO compensation to future share-price performance.

Negative

• Potential dilution: Full exercise could add 602,346 shares to the float.
• Process weakness: Initial Form 4 contained errors, implying internal control lapse over insider reporting.

Insights

Corporate Governance Expert

TL;DR – Administrative correction; improves disclosure, immaterial operational impact.

This Form 4/A merely fixes the strike price and expiration date of an already-reported CEO option grant. From a governance angle, the amendment is positive because it rectifies inaccurate information within one trading week, signalling the company’s commitment to Section 16 compliance. The 602,346-share option, vesting monthly over four years, is a standard retention tool for small-cap biopharma leadership. While the potential dilution is under 3% of a typical micro-cap share count, it occurs only if the stock exceeds $2.97 and vesting conditions are met. Overall, the event is neutral-to-slightly-positive in governance terms and has no direct effect on fundamentals.

Portfolio Manager

TL;DR – Neutral for valuation; highlights a 602k-share overhang at $2.97.

The corrected grant locks in a strike roughly at recent trading levels (exact market price not provided in the filing). Long-dated (10-year) options encourage value creation, yet also introduce an overhang equivalent to 602,346 shares. Because dilution is deferred and contingent on performance, I view the impact on near-term EPS or cash flow as immaterial. Absent other catalysts, the filing does not alter my position sizing in IKT.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Iwicki Mark T

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/25/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.97(1)	02/21/2025		A		602,346		(2)	02/21/2035(1)	Common Stock	602,346	$0	602,346	D

Explanation of Responses:

1. The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported the incorrect exercise price and expiration date with respect to the stock option award originally granted on February 21, 2025 (the "Option Award"). This amendment is being filed solely to correct the exercise price and expiration date of the Option Award.

2. The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 21, 2025, subject to the Reporting Person's continued employment through such date.

	/s/ Mark Iwicki	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What was corrected in Inhibikase Therapeutics' Form 4/A for ticker IKT?

The amendment fixes the $2.97 exercise price and 21 Feb 2035 expiration date of a CEO stock-option grant.

How many options were granted to CEO Mark T. Iwicki?

He received 602,346 stock options for common shares.

What is the vesting schedule for the IKT CEO option grant?

The options vest in 48 equal monthly installments beginning 21 Mar 2025, subject to continued employment.

Does the Form 4/A report any new share purchases or sales?

No. It solely corrects previously misstated terms; no shares were bought or sold.

Could the option grant dilute existing IKT shareholders?

Yes. If fully exercised, 602,346 new shares would be issued, increasing total share count.

What is the tenure of the corrected stock option?

The option expires on 21 Feb 2035, providing a 10-year exercise window.